Results 31 to 40 of about 2,929 (206)
Comparative Study Between the Efficacies of Vonoprazan Versus Omeprazole in Patients with Gastroesophageal Reflux Disease [PDF]
International Journal of Medical Arts, 2023 Background: The most common acid known abnormality is gastroesophageal reflux disease [GERD] which is treated by proton pump inhibitors [PPIs]. One of new family of gastric acid-suppressing medications is Vonoprazan that works as a potassium-competitive ...
Mohammed Mahdi +3 more
doaj +1 more source
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data [PDF]
, 2020 Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneous class of drugs that competitively block the potassium binding site of gastric H+/K+ ATPase, thus potentially overcoming the limitations of proton-pump ...
Barberio, Brigida +10 more
core +1 more source
Annals of Clinical Microbiology and Antimicrobials, 2018 Background All Helicobacter pylori-infected patients are recommended for eradication with an appropriate regimen in each geographic area. The choice of the therapy is somewhat dependent on the antimicrobial susceptibility.
Hiroki Tanabe +11 more
doaj +1 more source
Study of the Completion of Follow-up After Helicobacter Pylori Eradication Therapy [PDF]
, 2018 Background: Because no therapeutic regimens have an eradication rate of 100%, post-treatment evaluation is necessary to ensure that adequate eradication therapy for Helicobacter pylori has been provided. The fact that not all patients are evaluated after
Kajihara, Y. (Yusaku) +1 more
core +1 more source
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
Pharmaceuticals, 2020 Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H.
Muhammad Miftahussurur +2 more
doaj +1 more source
The role of vonoprazan in patients with erosive esophagitis
Therapeutic Advances in Gastroenterology, 2022 Acid suppression is the primary therapy for erosive esophagitis (EE). Although proton pump inhibitors (PPIs) are considered as the first-line medication for EE, 10–20% of patients with Los Angeles C and D grade EE do not gain complete mucosal healing and
Mengyu Zhang, Yinglian Xiao, Minhu Chen
doaj +1 more source
New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine [PDF]
, 2023 The strategic fluorination of oxidatively vulnerable sites in bioactive compounds is a relatively recent, widely used approach allowing us to modulate the stability, bio-absorption, and overall efficiency of pharmaceutical drugs.
Dhawan, Gagan +5 more
core +1 more source
JGH Open, 2023 Background and Aim Vonoprazan as a new acid blocker has more potency and longer lasting acid suppression than proton pump inhibitors. Whether the efficacy of vonoprazan‐based triple therapy is comparable with or even better than that of currently ...
Yu‐Tse Chiu +7 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4.
Sejung Hwang +7 more
doaj +1 more source
How Widespread and Convenient H. pylori Susceptibility Testing Will Result in Pharmacological Opportunities [PDF]
, 2023 Introduction: Until recently antimicrobial therapy for Helicobacter pylori infections was almost universally empirical and based on a combination of expert opinion and local effectiveness.
Graham, David Y, Rokkas, Theodore
core +2 more sources